Literature DB >> 8616842

Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.

H Yoshiji1, D E Gomez, M Shibuya, U P Thorgeirsson.   

Abstract

Angiogenesis is essential for the growth and metastasis of solid tumors. In this study, we examined gene expression of vascular endothelial growth factor (VEGF); its receptor, flt-1; basic fibroblast growth factor; and transforming growth factors (TGFs) alpha and beta in 18 paired cases of human breast carcinomas and the adjacent nonneoplastic tissues. In all of the paired cases, VEGF expression was markedly increased in the carcinomas. In contrast, an insignificant difference was observed in the expression of flt-1, basic fibroblast growth factor, TGF-alpha, and TGF-beta between the malignant breast tissue and the nonneoplastic counterpart. Immunostaining showed variable VEGF positivity of the malignant cells, whereas the nonneoplastic breast epithelial cells were negative. The findings of this study suggest that VEGF is an important angiogenic factor in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616842

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  80 in total

1.  Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.

Authors:  Hai B Zhou; Yi F Yin; Yan Hu; Xin Li; Li Y Zou; Yong J Li; Yu Gu; Bao Q Ou; Juan Fu; Jun H Du; Gang Wu
Journal:  Jpn J Radiol       Date:  2011-09-29       Impact factor: 2.374

Review 2.  The value of coronary angiography in the work-up of atrial myxomas.

Authors:  H R Omar
Journal:  Herz       Date:  2013-11-01       Impact factor: 1.443

3.  Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.

Authors:  Di Jia; Sean M Hasso; Joanne Chan; Domenic Filingeri; Patricia A D'Amore; Lori Rice; Christine Pampo; Dietmar W Siemann; David Zurakowski; Scott J Rodig; Marsha A Moses
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

Review 4.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

5.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

6.  A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

Authors:  Henry Q Xiong; Roy Herbst; Silvana C Faria; Catherine Scholz; Darren Davis; Edward F Jackson; Timothy Madden; David McConkey; Marshall Hicks; Kenneth Hess; Chusilp Arthur Charnsangavej; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

8.  High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.

Authors:  Issam Makhoul; Robert J Griffin; Eric Siegel; Jeannette Lee; Ishwori Dhakal; Vinay Raj; Azemat Jamshidi-Parsian; Suzanne Klimberg; Laura F Hutchins; Susan Kadlubar
Journal:  Am J Clin Oncol       Date:  2016-06       Impact factor: 2.339

9.  Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer.

Authors:  E-M Boneberg; D F Legler; M M Hoefer; C Ohlschlegel; H Steininger; L Füzesi; G M Beer; V Dupont-Lampert; F Otto; H-J Senn; G Fürstenberger
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

10.  Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.

Authors:  M Javle; J Yu; C Garrett; A Pande; B Kuvshinoff; A Litwin; J Phelan; J Gibbs; R Iyer
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.